Histone Deacetylase 7 protects against pathologic cardiac hypertrophy
Authors:
Open Access
- 5 June 2026
- journal article
- Published by Elsevier in Journal of Molecular and Cellular Cardiology
- Vol. 217, 40-50
Abstract
No abstract availableKeywords
Funding Information
- National Heart, Lung, and Blood Institute (HL176685)
- National Heart, Lung, and Blood Institute (HL153406)
- Case Western Reserve University
- American Heart Association
This publication has 47 references indexed in Scilit:
- How common is hypertrophic cardiomyopathy… really?: Disease prevalence revisited 27 years after CARDIAInternational Journal of Cardiology, 2023
- Exosomes mediated fibrogenesis in dilated cardiomyopathy through a MicroRNA pathwayiScience, 2023
- Diverse origins and activation of fibroblasts in cardiac fibrosisCellular Signalling, 2021
- Epigenetics in Cardiac Hypertrophy and Heart FailureJACC: Basic To Translational Science, 2019
- Fibroblasts in the Infarcted, Remodeling, and Failing HeartJACC: Basic To Translational Science, 2019
- Regulation of fetal gene expression in heart failureBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2013
- Histone deacetylase 7 (HDAC7) regulates myocyte migration and differentiationBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2010
- Histone deacetylase inhibitors: Potential in cancer therapyJournal of Cellular Biochemistry, 2009
- Histone Deacetylase 7 Maintains Vascular Integrity by Repressing Matrix Metalloproteinase 10Cell, 2006
- Histone Deacetylase 4 Controls Chondrocyte Hypertrophy during SkeletogenesisCell, 2004